Management has done really well in what they could. But there is...

Management has done really well in what they could. But there is no hiding the disappointments that a) FDA approval is not yet forthcoming, and b) no customer in the US has signed up yet. Given the crowdedness of the market, I suspect that the US opportunity is probably lost. Had EUA been granted in May, it would have been a very different story. We could be looking at upward towards >50m revenue in 2021 and sound profitability to lay the financial foundation for further product development. I suspect the reason is in the disfunctional FDA during the chaotic months. But regardless the net result for us shareholders is that GSS wasn't lucky enough to break early into the US market.